AstraZeneca Vaccine Administration and Treatment Outcomes  in Cardiovascular Patients

Phoebe Clarissa Chastity; Diana Laila Ramatillah

doi:10.36590/jika.v7i2.1068

Authors

Phoebe Clarissa Chastity Pharmacy Study Program, Faculty of Pharmacy, University of August 17, 1945 Jakarta, Jakarta, Indonesia
Diana Laila Ramatillah Pharmacy Study Program, Faculty of Pharmacy, University of August 17, 1945 Jakarta, Jakarta, Indonesia

DOI:

https://doi.org/10.36590/jika.v7i2.1068

Keywords:

AstraZeneca vaccine, cardiovascular, correlation analysis

Abstract

Cardiovascular disease (CVD) is a leading cause of morbidity and mortality worldwide. With the global rollout of COVID-19 vaccines, including the AstraZeneca vaccine, there is increasing interest in understanding their impact on individuals with pre-existing cardiovascular conditions. While effective in preventing COVID-19, concerns have been raised about potential cardiovascular side effects. This study aimed to determine the correlation between the AstraZeneca vaccine and treatment outcomes in CVD patients, focusing on differences in patients' CVD-related conditions before and after vaccination. Data were collected using validated questionnaires conducted in Jakarta, employing an analytical survey with a cohort approach. Reliability was assessed using Cronbach's alpha, and validity was tested with a modified Delphi method involving clinical pharmacy experts. Data were analyzed using crosstab analysis via Chi-square test. The study included 200 subjects, with 115 females (57,5%) and 85 males (42,5%), with a majority of participants being over 45 years old (45,0%). A significant correlation (p-value < 0,05) was observed across various factors, including comorbidities and sociodemographic variables, patients' drug intake before and after vaccination, and the relationship between vaccination and comorbid diseases. The findings indicate a strong association between vaccination and patients history of cardiovascular disease. This correlation highlights the vaccine's possible impact on CVD-related symptoms post-vaccination. Consequently, the research provides evidence that the AstraZeneca vaccination significantly affects the risk of cardiovascular disease.

Downloads

Download data is not yet available.

Author Biographies

Phoebe Clarissa Chastity, Pharmacy Study Program, Faculty of Pharmacy, University of August 17, 1945 Jakarta, Jakarta, Indonesia

Pharmacy Study Program, Faculty of Pharmacy, University of August 17, 1945 Jakarta, Jakarta, Indonesia

Diana Laila Ramatillah, Pharmacy Study Program, Faculty of Pharmacy, University of August 17, 1945 Jakarta, Jakarta, Indonesia

Pharmacy Study Program, Faculty of Pharmacy, University of August 17, 1945 Jakarta, Jakarta, Indonesia

https://scholar.google.com

References

Abbas, M., Malicke, D.T., Schramski, J.T., 2020. Stroke Anticoagulation (Archived). StatPeals Publishing, New York.

Arif, Y., Stefanko, A., Garcia, N.J., Beshai, D., Fan, W., Wong, N.D., 2022. Relation of 10-Year Ascvd Risk Score with Severe Covid-19 Outcomes. Journal of The American College of Cardiology 79(9), 1-12. Doi:Https://Doi.Org/10.1016/S0735-1097(22)02839-X=[=[

Buddeke, J., Bots, M.L., Dis, I.V., Visseren, F.L., Hollander, M., Schellevis, F.G., Vaartjes, I., 2019. Comorbidity in Patients with Cardiovascular Disease in Primary Care: A Cohort Study with Routine Healthcare Data. British Journal of General Practice 69(683), E398–E406. DOI: https://doi.org/10.3399/bjgp19X702725

Chen, C.Y., Su, T.C., 2023. Benefits and Harms of Covid-19 Vaccines in Cardiovascular Disease: A Comprehensive Review. Journal of Lipid and Atherosclerosis 12(2), 119–119. Doi:Https://Doi.Org/10.12997/Jla.2023.12.2.119

Kaswandani, N., Medise, B.E., Leonard, E., Satari, H.I., Sundoro, J., Hadinegoro, S.R.H., Putra, A., Angkasa, P.F., 2023. Safety Profile of Inactivated Covid-19 in Healthy Adults Aged ≥ 18 Years: A Passive Surveillance in Indonesia. Plos One 18(10), 1-22. Doi:Https://Doi.Org/10.1371/Journal.Pone.0286484

Liu, R., Pan, J., Zhang, C., Sun, X., 2022. Cardiovascular Complications of Covid-19 Vaccines. Frontiers in Cardiovascular Medicine 9, 1-7. Doi:Https://Doi.Org/10.3389/Fcvm.2022.840929

Ministry of Health., 2021. Clinical Guidelines on Covid-19 Vaccination in Malaysia 4th Edition. Ministry of Health Malaysia, Kuala Lumpur.

Rodgers, J.L., Jones, J., Bolleddu, S.I., Vanthenapalli, S., Rodgers, L.E., Shah, K., Karia, K., Panguluri, S.K., 2019. Cardiovascular Risks Associated with Gender and Aging. Journal of Cardiovascular Development and Disease 6(2), 1-18. Doi:Https://Doi.Org/10.3390/Jcdd6020019

Sette, A., Crotty, S., 2021. Adaptive Immunity to Sars-Cov-2 and Covid-19. Cell 184(4), 861–880. Doi:Https://Doi.Org/10.1016/J.Cell.2021.01.007

Shiravi, A.A., Ardekani, A., Sheikhbahaei, E., Heshmat-Ghahdarijani, K., 2021. Cardiovascular Complications of Sars-Cov-2 Vaccines: An Overview. Cardiology and Therapy 11(1), 13-21. Doi:Https://Doi.Org/10.1007/S40119-021-00248-0

Speiser, D.E., Bachmann, M.F., 2020. Covid-19: Mechanisms of Vaccination and Immunity. Vaccines 8(3), 1-19. Doi:Https://Doi.Org/10.3390/Vaccines8030404

Trimawartinah, T., 2020. Bahan Ajar Statistik Non Parametrik. [Modul]. Universitas Muhammadiyah Prof. Dr. Hamka, Jakarta.

Varga, Z., Flammer, A.J., Steiger, P., Haberecker, M., Andermatt, R., Zinkernagel, A.S., Mehra, M.R., Schuepbach, R.A., Ruschitzka, F., Moch, H., 2020. Endothelial Cell Infection and Endotheliitis in Covid-19. The Lancet 395(10234), 1417-1418. Doi:Https://Doi.Org/10.1016/S0140-6736(20)30937-5

Vionalita, G., 2020. Modul Metodologi Penelitian Kuantitatif (KSM361) Materi 4 Kerangka Konsep dan Defenisi Operasional. Universitas Esa Unggul, Jakarta.

[WHO] World Health Organization., 2021. WHO-Convened Global Study of Origins of Sars-Cov-2: China Part [WWW Document]. https://www.who.int/Publications/I/Item/Who-Convened-Global-Study-Of-Origins-Of-Sars-Cov-2-China-Part. [Diakses Mei 2025].